Home / Latest Reports / Pharmacovigilance Pv Market

Pharmacovigilance (PV) Market By Trial Phase, Service Provider, Type and End User - Global Industry Analysis and Forecast to 2023

Published On : April 2018 Pages : 100 Category: Healthcare IT Report Code : HC04677

Request Sample Inquiry Before Buying Request for Customization Check Discount

Industry Outlook and Trend Analysis

The Pharmacovigilance (PV) Market was worth USD 2.78 billion in 2017 and is expected to reach approximately USD 8.46 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 13.14% during the forecast period. Expanding rate of Adverse Drug Reactions (ADRs) is anticipated to quicken the interest for pharmacovigilance services over the conjecture time frame. Developing prevalence of chronic diseases is another significant benefactor for the PV development. Treatment of these chronic diseases require uptake of blend of medications bringing about ADR. To curtail this issue, PV administrations are used. Also, presence of charitable association for spreading the awareness associated with PV, for example, International Society of Pharmacovigilance (ISoP) is anticipated to encourage the selection of PV amid the conjecture time frame as it is concentrating on upgrading safe and appropriate use of medications at worldwide level. Increasing government activities relating to adoption of PV administrations is foreseen to impel the business development in the following years.

Clinical Trial Phase Outlook and Trend Analysis

The Phase IV (Post marketing) clinical trial section ruled the market in 2017. PV arrangements function as an extra security measure for the drug undergoing clinical trials. Stage IV is fundamental phase of whole clinical trials as unsuspected unfavourable medication responses can be recognized in this stage. Consequently, the information gathered and surveyed amid this stage is anticipated to be of the most elevated significance. The Phase III section is foreseen to witness lucrative development.

Service Provider Outlook and Trend Analysis

Contract outsourcing held the prevailing share in 2017 and is anticipated to witness quickest developing fragment in the following years. It is because of the advantages related with outsourcing such as resource flexibility, risk mitigation, reduction in fixed cost, and reduction of upfront investments. Contract outsourcing associations give arrangements, for example, process plan Standard Operating Procedure (SOP), PV audits, and other customized services.

Type Outlook and Trend Analysis

Spontaneous reporting captured the biggest share of the pharmacovigilance market in 2017, attributable to wide usage in location of new, genuine and uncommon ADRs and serves as a proficient and economical technique. Wide use of surveillance reports created through this technique by pharmaceutical organizations and regulatory authorities is likewise in charge of capitalizing the share of the overall industry of spontaneous reporting. Cohort event monitoring (CEM) is anticipated to be the quickest developing fragment inferable from its expanding application in discovery of extensive variety of unfavourable clinical events.

End User outlook and Trend Analysis

In 2017, hospitals represented the biggest revenue share of the pharmacovigilance market based on end use. Hospitals serves columnist associations, which report the ADRs, happened amid a specific time period, to administrative experts keeping in mind the end goal to find out the requirement for post marketing surveillance. Rising frequency of ADRs and medication errors are anticipated to drive the hospital section development over the gauge time frame.

Regional Outlook and Trend Analysis

North America captured the biggest revenue share in 2017, attributable to presence of key pharmaceutical and medicinal devices players in this area, adding to the general income in this area. Rising level of drug abuse and related unfavourable drug reactions is a main source of death and morbidity. The previously mentioned components are high development rendering factors for the pharmacovigilance market in North America. Asia Pacific is anticipated to develop at lucrative rate, owing to accessibility of expansive number of outsourcing associations.

Competitive Insights

The leading players in the market are BioClinica, LabCorp, Capgemini, Clinquest Group B.V, iMEDGlobal, ITClinical, Cognizant, ArisGlobal LLC, ICON plc, IBM and Accenture. This industry is witnessing a tremendous boost due to patent expiration of branded drugs and rising number of new drug developments. This has encouraged several local and international pharmacovigilance service providers in the market.

The Pharmacovigilance (PV) Market is segmented as follows-

By Clinical Trial Phase:

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Service Provider:

  • In-house
  • Contract Outsourcing

By Type:

  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Spontaneous Reporting
  • EHR Mining
  • Cohort Event Monitoring

By End User:

  • Research Organizations
  • Hospitals
  • Industrial

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • South Africa
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2023?
  • What will be the industry market growth from 2017 to 2023?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Pharmacovigilance (PV) Market, By Trial Phase, Estimates and Forecast, 2014-2023 ($Million)

·         Pre-clinical

·         Phase I

·         Phase II

·         Phase III

·         Phase IV

·         Pharmacovigilance (PV) Market, By Service Provider, Estimates and Forecast, 2014-2023 ($Million)

·         In-house

·         Contract Outsourcing

·         Pharmacovigilance (PV) Market, By Type, Estimates and Forecast, 2014-2023 ($Million)

·         Spontaneous Reporting

·         Intensified ADR Reporting

·         Targeted Spontaneous Reporting

·         Cohort Event Monitoring

·         EHR Mining

·         Pharmacovigilance (PV) Market, By End User, Estimates and Forecast, 2014-2023 ($Million)

·         Hospitals

·         Research Organizations

·         Industrial

·         Pharmacovigilance (PV) Market, By Region, Estimates and Forecast, 2014-2023 ($Million)

o    North America

§  North America Pharmacovigilance (PV) Market, By Country

o    U.S. Pharmacovigilance (PV) Market

o    Canada Pharmacovigilance (PV) Market

o    Mexico Pharmacovigilance (PV) Market

o    Europe

§  Europe Pharmacovigilance (PV) Market, By Country

o    Germany Pharmacovigilance (PV) Market

o    UK Pharmacovigilance (PV) Market

o    France Pharmacovigilance (PV) Market

o    Russia Pharmacovigilance (PV) Market

o    Italy Pharmacovigilance (PV) Market

o    Rest of Europe Pharmacovigilance (PV) Market

o    Asia-Pacific

§  Asia-Pacific Pharmacovigilance (PV) Market, By Country

o    China Pharmacovigilance (PV) Market

o    Japan Pharmacovigilance (PV) Market

o    South Korea Pharmacovigilance (PV) Market

o    India Pharmacovigilance (PV) Market

o    Southeast Asia Pharmacovigilance (PV) Market

o    Rest of Asia-Pacific Pharmacovigilance (PV) Market

o    South America

§  South America Pharmacovigilance (PV) Market

o    Brazil Pharmacovigilance (PV) Market

o    Argentina Pharmacovigilance (PV) Market

o    Columbia Pharmacovigilance (PV) Market

o    South Africa Pharmacovigilance (PV) Market

o    Rest of South America Pharmacovigilance (PV) Market

o    Middle East and Africa

§  Middle East and Africa Pharmacovigilance (PV) Market

o    Saudi Arabia Pharmacovigilance (PV) Market

o    UAE Pharmacovigilance (PV) Market

o    Egypt Pharmacovigilance (PV) Market

o    Nigeria Pharmacovigilance (PV) Market

o    South Africa Pharmacovigilance (PV) Market

o    Rest of MEA Pharmacovigilance (PV) Market

Table of Contents

1.       Introduction

1.1.       Report Description

1.2.       Research Methodology

1.2.1.  Secondary Research

1.2.2.  Primary Research

2.       Executive Summary

2.1.       Key Highlights

3.       Market Overview

3.1.       Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.       Market Dynamics

3.2.1.  Drivers

3.2.1.1.    Increasing Incidence Rates of ADR and Drug Toxicity

3.2.1.2.    Growing Drug Consumption and Drug Development Rates

3.2.2.  Restraints

3.2.2.1.    Lack of Skilled Labor

3.2.3.  Opportunities

3.2.3.1.    Emerging Markets to Offer Lucrative Growth Opportunities

4.       Market Analysis by Regions

4.1.       North America (United States, Canada and Mexico)

4.1.1.  United States Market States and Outlook (2017-2023)

4.1.2.  Canada Market States and Outlook (2017-2023)

4.1.3.  Mexico Market States and Outlook (2017-2023)

4.2.       Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market States and Outlook (2017-2023)

4.2.2.  France Market States and Outlook (2017-2023)

4.2.3.  UK Market States and Outlook (2017-2023)

4.2.4.  Russia Market States and Outlook (2017-2023)

4.2.5.  Italy Market States and Outlook (2017-2023)

4.2.6.  Rest of Europe Market States and Outlook (2017-2023)

4.3.       Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market States and Outlook (2017-2023)

4.3.2.  Japan Market States and Outlook (2017-2023)

4.3.3.  Korea Market States and Outlook (2017-2023)

4.3.4.  India Market States and Outlook (2017-2023)

4.3.5.  Rest of Asia-Pacific Market States and Outlook (2017-2023)

4.4.       South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market States and Outlook (2017-2023)

4.4.2.  Argentina Market States and Outlook (2017-2023)

4.4.3.  Columbia Market States and Outlook (2017-2023)

4.4.4.  Rest of South America Market States and Outlook (2017-2023)

4.5.       Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market States and Outlook (2017-2023)

4.5.2.  UAE Market States and Outlook (2017-2023)

4.5.3.  Egypt Market States and Outlook (2017-2023)

4.5.4.  Nigeria Market States and Outlook (2017-2023)

4.5.5.  South Africa Market States and Outlook (2017-2023)

4.5.6.  Rest of MEA Market States and Outlook (2017-2023)

5.       Pharmacovigilance (PV) Market, By Trial Phase

5.1.       Introduction

5.2.       Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Trial Phase (2017-2027)

5.2.1.  Global Pharmacovigilance (PV) Sales and Sales Share by Trial Phase (2017-2027)

5.2.2.  Global Pharmacovigilance (PV) Revenue and Revenue Share by Trial Phase (2017-2027)

5.3.       Pre-clinical

5.3.1.  Global Pre-clinical Sales and Growth Rate (2017-2027)

5.4.       Phase I

5.4.1.  Global Phase I Sales and Growth Rate (2017-2027)

5.5.       Phase II

5.5.1.  Global Phase II Sales and Growth Rate (2017-2027)

5.6.       Phase III

5.6.1.  Global Phase III Sales and Growth Rate (2017-2027)

5.7.       Phase IV

5.7.1.  Global Phase IV Sales and Growth Rate (2017-2027)

6.       Pharmacovigilance (PV) Market, By Service Provider

6.1.       Introduction

6.2.       Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Service Provider (2017-2027)

6.2.1.  Global Pharmacovigilance (PV) Sales and Sales Share by Service Provider (2017-2027)

6.2.2.  Global Pharmacovigilance (PV) Revenue and Revenue Share by Service Provider (2017-2027)

6.3.       In-house

6.3.1.  Global Under In-house Sales and Growth Rate (2017-2027)

6.4.       Contract Outsourcing

6.4.1.  Global Contract Outsourcing Sales and Growth Rate (2017-2027)

7.       Pharmacovigilance (PV) Market, By Type

7.1.       Introduction

7.2.       Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Type (2017-2027)

7.2.1.  Global Pharmacovigilance (PV) Sales and Sales Share by Type (2017-2027)

7.2.2.  Global Pharmacovigilance (PV) Revenue and Revenue Share by Type (2017-2027)

7.3.       Spontaneous Reporting

7.3.1.  Global Spontaneous Reporting Sales and Growth Rate (2017-2027)

7.4.       Intensified ADR Reporting

7.4.1.  Global Intensified ADR Reporting Sales and Growth Rate (2017-2027)

7.5.       Targeted Spontaneous Reporting

7.5.1.  Global Targeted Spontaneous Reporting Sales and Growth Rate (2017-2027)

7.6.       Cohort Event Monitoring

7.6.1.  Global Cohort Event Monitoring Sales and Growth Rate (2017-2027)

7.7.       EHR Mining

7.7.1.  Global EHR Mining Sales and Growth Rate (2017-2027)

8.       Pharmacovigilance (PV) Market, By End User

8.1.       Introduction

8.2.       Global Pharmacovigilance (PV) Sales, Revenue and Market Share by End User (2017-2027)

8.2.1.  Global Pharmacovigilance (PV) Sales and Sales Share by End User (2017-2027)

8.2.2.  Global Pharmacovigilance (PV) Revenue and Revenue Share by End User (2017-2027)

8.3.       Hospitals

8.3.1.  Global Hospital Pharmacies Sales and Growth Rate (2017-2027)

8.4.       Research Organizations

8.4.1.  Global Research Organizations Sales and Growth Rate (2017-2027)

8.5.       Industrial

8.5.1.  Global Industrial Sales and Growth Rate (2017-2027)

9.       Pharmacovigilance (PV) Market, By Region

9.1.       Introduction

9.2.       Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Regions

9.2.1.  Global Pharmacovigilance (PV) Sales by Regions (2017-2027)

9.2.2.  Global Pharmacovigilance (PV) Revenue by Regions (2017-2027)

9.3.       North America Pharmacovigilance (PV) by Countries

9.3.1.  North America Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.3.2.  North America Pharmacovigilance (PV) Revenue and Growth Rate (2017-2027)

9.3.3.  North America Pharmacovigilance (PV) Sales by Countries (2017-2027)

9.3.4.  North America Pharmacovigilance (PV) Revenue (Million USD) by Countries (2017-2027)

9.3.5.  U.S.

9.3.5.1.    United States Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.3.5.2.    United States Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.3.6.  Canada

9.3.6.1.    Canada Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.3.6.2.    Canada Pharmacovigilance (PV) Sales (Millions USD) and Growth Rate (2017-2027)

9.3.7.  Mexico

9.3.7.1.    Mexico Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.3.7.2.    Mexico Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.       Europe Pharmacovigilance (PV) by Countries

9.4.1.  Europe Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.2.  Europe Pharmacovigilance (PV) Revenue and Growth Rate (2017-2027)

9.4.3.  Europe Pharmacovigilance (PV) Sales by Countries (2017-2027)

9.4.4.  Europe Pharmacovigilance (PV) Revenue (Million USD) by Countries (2017-2027)

9.4.5.  Germany

9.4.5.1.    Germany Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.5.2.    Germany Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.6.  UK

9.4.6.1.    UK Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.6.2.    UK Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.7.  France

9.4.7.1.    France Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.7.2.    France Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.8.  Russia

9.4.8.1.    Russia Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.8.2.    Russia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.9.  Italy

9.4.9.1.    Italy Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.9.2.    Italy Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.4.10.      Rest of Europe

9.4.10.1. Rest of Europe Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.4.10.2. Rest of Europe Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.       Asia-Pacific

9.5.1.  Asia-Pacific Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.2.  Asia-Pacific Pharmacovigilance (PV) Revenue and Growth Rate (2017-2027)

9.5.3.  Asia-Pacific Pharmacovigilance (PV) Sales by Countries (2017-2027)

9.5.4.  Asia-Pacific Pharmacovigilance (PV) Revenue (Million USD) by Countries (2017-2027)

9.5.5.  China

9.5.5.1.    China Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.5.2.    China Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.6.  Japan

9.5.6.1.    Japan Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.6.2.    Japan Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.6.3.     

9.5.7.  Korea

9.5.7.1.    Korea Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.7.2.    Korea Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.8.  India

9.5.8.1.    India Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.8.2.    India Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.9.  Southeast Asia

9.5.9.1.    Southeast Asia Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.9.2.    Southeast Asia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.5.10.      Rest of Asia-Pacific

9.5.10.1. Rest of Asia-Pacific Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.5.10.2. Rest of Asia-Pacific Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.6.       South America

9.6.1.  South America Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.6.2.  South America Pharmacovigilance (PV) Revenue and Growth Rate (2017-2027)

9.6.3.  South America Pharmacovigilance (PV) Sales by Countries (2017-2027)

9.6.4.  South America Pharmacovigilance (PV) Revenue (Million USD) by Countries (2017-2027)

9.6.5.  Brazil

9.6.5.1.    Brazil Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.6.5.2.    Brazil Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.6.6.  Argentina

9.6.6.1.    Argentina Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.6.6.2.    Argentina Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.6.7.  Columbia

9.6.7.1.    Columbia Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.6.7.2.    Columbia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.6.8.  Rest of South America

9.6.8.1.    Rest of South America Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.6.8.2.    Rest of South America Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.       Middle East and Africa

9.7.1.  Middle East and Africa Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.2.  Middle East and Africa Pharmacovigilance (PV) Revenue and Growth Rate (2017-2027)

9.7.3.  Middle East and Africa Pharmacovigilance (PV) Sales by Countries (2017-2027)

9.7.4.  Middle East and Africa Pharmacovigilance (PV) Revenue (Million USD) by Countries (2017-2027)

9.7.5.  Saudi Arabia

9.7.5.1.    Saudi Arabia Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.5.2.    Saudi Arabia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.6.  United Arab Emirates

9.7.6.1.    United Arab Emirates Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.6.2.    United Arab Emirates Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.7.  Egypt

9.7.7.1.    Egypt Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.7.2.    Egypt Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.8.  Nigeria

9.7.8.1.    Nigeria Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.8.2.    Nigeria Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.9.  South Africa

9.7.9.1.    South Africa Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.9.2.    South Africa Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

9.7.10.      Rest of Middle East and Africa

9.7.10.1. Rest of Middle East and Africa Pharmacovigilance (PV) Sales and Growth Rate (2017-2027)

9.7.10.2. Rest of Middle East and Africa Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2017-2027)

10.   Company Profiles

10.1.      Accenture

10.1.1.      Business Overview

10.1.2.      Product Portfolio

10.1.3.      Strategic Developments

10.1.4.      Sales, Revenue and Market Share

10.2.    Clinquest Group B.V.

10.2.1.      Business Overview

10.2.2.      Product Portfolio

10.2.3.      Strategic Developments

10.2.4.      Sales, Revenue and Market Share

10.3.    Cognizant

10.3.1.      Business Overview

10.3.2.      Product Portfolio

10.3.3.      Strategic Developments

10.3.4.      Sales, Revenue and Market Share

10.4.    Laboratory Corporation of America Holdings

10.4.1.      Business Overview

10.4.2.      Product Portfolio

10.4.3.      Strategic Developments

10.4.4.      Sales, Revenue and Market Share

10.5.    IBM Corporation

10.5.1.      Business Overview

10.5.2.      Product Portfolio

10.5.3.      Strategic Developments

10.5.4.      Sales, Revenue and Market Share

10.6.    ArisGlobal

10.6.1.      Business Overview

10.6.2.      Product Portfolio

10.6.3.      Strategic Developments

10.6.4.      Sales, Revenue and Market Share

10.7.     ICON plc

10.7.1.      Business Overview

10.7.2.      Product Portfolio

10.7.3.      Strategic Developments

10.7.4.      Sales, Revenue and Market Share

10.8.    Capgemini

10.8.1.      Business Overview

10.8.2.      Product Portfolio

10.8.3.      Strategic Developments

10.8.4.      Sales, Revenue and Market Share

10.9.    ITClinical

10.9.1.      Business Overview

10.9.2.      Product Portfolio

10.9.3.      Strategic Developments

10.9.4.      Sales, Revenue and Market Share

10.10.iMEDGlobal

10.10.1.  Business Overview

10.10.2.  Product Portfolio

10.10.3.  Strategic Developments

10.10.4.  Sales, Revenue and Market Share

11.   Global Pharmacovigilance (PV) Market Competition, by Manufacturer

11.1.    Global Pharmacovigilance (PV) Sales and Market Share by Manufacturer (2017-2017)

11.2.    Global Pharmacovigilance (PV) Revenue and Market Share by Manufacturer (2017-2017)

11.3.    Global Pharmacovigilance (PV) Price by Manufacturer (2017-2017)

11.4.    Top 5 Pharmacovigilance (PV) Manufacturer Market Share

11.5.    Market Competition Trend

12.   Pharmacovigilance (PV) Market Forecast (2027-2023)

12.1.    Global Pharmacovigilance (PV) Sales, Revenue (Millions USD) and Growth Rate (2027-2023)

12.2.    Pharmacovigilance (PV) Market Forecast by Regions (2027-2023)

12.2.1.      North America Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.1.1. United States Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.1.2. Canada Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.1.3. Mexico Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.      Europe Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.1. Germany Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.2. United Kingdom Pharmacovigilance (PV)s Market Forecast (2027-2023)

12.2.2.3. France Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.4. Russia Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.5. Italy Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.2.6. Rest of the Europe Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.      Asia-Pacific Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.1. China Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.2. Japan Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.3. Korea Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.4. India Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.5. Southeast Asia Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.3.6. Rest of Asia-Pacific Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.4.      South America Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.4.1. Brazil Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.4.2. Argentina Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.4.3. Columbia Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.4.4. Rest of South America Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.      Middle East and Africa Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.1. Saudi Arabia Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.2. UAE Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.3. Egypt Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.4. Nigeria Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.5. South Africa Pharmacovigilance (PV) Market Forecast (2027-2023)

12.2.5.6. Rest of MEA Pharmacovigilance (PV) Market Forecast (2027-2023)

12.3.    Pharmacovigilance (PV) Market Forecast by Trial Phase (2027-2023)

12.3.1.      Global Pharmacovigilance (PV) Sales Forecast by Trial Phase (2027-2023)

12.3.2.      Global Pharmacovigilance (PV) Sales Market Share Forecast by Trial Phase (2027-2023)

12.4.    Pharmacovigilance (PV) Market Forecast by Service Provider (2027-2023)

12.4.1.      Global Pharmacovigilance (PV) Sales Forecast by Service Provider (2027-2023)

12.4.2.      Global Pharmacovigilance (PV) Sales Market Share Forecast by Service Provider (2027-2023)

12.5.    Pharmacovigilance (PV) Market Forecast by Type (2027-2023)

12.5.1.      Global Pharmacovigilance (PV) Sales Forecast by Type (2027-2023)

12.5.2.      Global Pharmacovigilance (PV) Sales Market Share Forecast by Type (2027-2023)

12.6.      Pharmacovigilance (PV) Market Forecast by End User (2027-2023)

12.6.1.      Global Pharmacovigilance (PV) Sales Forecast by End User (2027-2023)

12.6.2.      Global Pharmacovigilance (PV) Sales Market Share Forecast by End User (2027-2023)

List of Tables

*You can glance through the list of Tables and Figures when you view the sample copy of Pharmacovigilance (PV) Market.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*